The Economic Value of New Treatments for Depression

抑郁症新疗法的经济价值

• 批准号: 6738853
• 负责人: Rena Marie Conti
• 金额: $ 2.8万
• 依托单位: HARVARD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-12 至 2006-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6738853
• 关键词: antidepressants; decision making; depression; health care policy; health economics; literature survey; mental disorder chemotherapy; predoctoral investigator

Depression is a prevalent chronic condition nationally and is associated with high levels of impairment. Extraordinary advances have been achieved in the last two decades in the pharmacological treatment of deppression. The introduduction of these agents has altered the way in which depression is treated in the US and may have a large impact of individuals and their well-being. New treatments are also more expensive than older medications and are associated with remarkable increases in spending. The principal goal of this research is to develop practical, aggregate measures of the economic value of new methods for treating depression. I propose to measure the economic welfare generated by innovation in depression treatment by estimating a demand system that explicitly accounts for some unique features of the delivery of mental health care. From the demand estimates, several types of commonly used measures of welfare gain for the treatment of depression will be constructed. There are several competing approaches to measuring welfare change from innovation, of which the demand side approach is one. Welfare gains using the demand side approach will be compared to alternative measures.

抑郁症在全国范围内是一种普遍的慢性疾病，与高水平的损害有关。在过去的二十年中，抑郁症的药物治疗取得了非凡的进展。这些药物的引入改变了美国治疗抑郁症的方式，并可能对个人和家庭产生重大影响